Savara (NASDAQ:SVRA) Shares Up 4.1% – Here’s What Happened

Savara Inc (NASDAQ:SVRA) rose 4.1% during mid-day trading on Tuesday . The stock traded as high as $3.05 and last traded at $3.02. Approximately 101,330 shares traded hands during mid-day trading, a decline of 92% from the average daily volume of 1,328,423 shares. The stock had previously closed at $2.90.

Analysts Set New Price Targets

SVRA has been the topic of several research analyst reports. JMP Securities reaffirmed a “market outperform” rating and issued a $9.00 price objective on shares of Savara in a research report on Thursday, December 19th. Wells Fargo & Company assumed coverage on Savara in a report on Friday, December 20th. They issued an “overweight” rating and a $8.00 price target for the company. Finally, HC Wainwright reissued a “buy” rating and set a $6.00 target price on shares of Savara in a research report on Friday, March 28th. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $8.83.

Savara Stock Performance

The firm’s fifty day moving average price is $2.72 and its two-hundred day moving average price is $3.11. The company has a current ratio of 17.70, a quick ratio of 17.70 and a debt-to-equity ratio of 0.13. The stock has a market capitalization of $510.99 million, a PE ratio of -6.88 and a beta of 0.52.

Savara (NASDAQ:SVRA) last posted its quarterly earnings data on Thursday, March 27th. The company reported ($0.13) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.02). The business had revenue of $0.27 million for the quarter. As a group, equities research analysts forecast that Savara Inc will post -0.45 EPS for the current year.

Institutional Investors Weigh In On Savara

Several hedge funds and other institutional investors have recently made changes to their positions in SVRA. The Manufacturers Life Insurance Company grew its stake in shares of Savara by 9.0% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 44,956 shares of the company’s stock valued at $191,000 after buying an additional 3,706 shares during the period. Altium Capital Management LLC lifted its position in Savara by 0.3% in the fourth quarter. Altium Capital Management LLC now owns 1,579,000 shares of the company’s stock valued at $4,848,000 after buying an additional 4,000 shares during the last quarter. China Universal Asset Management Co. Ltd. increased its position in shares of Savara by 14.9% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 36,390 shares of the company’s stock valued at $112,000 after acquiring an additional 4,732 shares during the last quarter. Price T Rowe Associates Inc. MD raised its stake in shares of Savara by 13.6% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 43,668 shares of the company’s stock valued at $135,000 after acquiring an additional 5,236 shares during the period. Finally, Dimensional Fund Advisors LP lifted its holdings in shares of Savara by 3.9% in the 4th quarter. Dimensional Fund Advisors LP now owns 143,661 shares of the company’s stock worth $441,000 after acquiring an additional 5,450 shares during the last quarter. Institutional investors and hedge funds own 87.93% of the company’s stock.

Savara Company Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.